Nitto Avecia Inc. has successfully completed the first synthesis runs at 1.6 Mol scale at its new oligonucleotide manufacturing facility in Milford, MA. According to the company, this is believed to be the largest synthesis scale executed for oligonucleotide API (active pharmaceutical ingredients).

The company recently began operations with its new API manufacturing synthesis capabilities. This manufacturing capacity expansion increases Avecia’s total synthesis capacity to more than 3 Mol.

Nitto Avecia’s president Detlef Rethage said, “Avecia’s leadership in the oligonucleotide market is significant and we are proud to have added this major manufacturing scale in less than two years to address a capacity shortage that could have slowed down our client’s clinical trial progress. With our 1.6 Mol synthesis capabilities now operational, the capacity shortage in oligonucleotides manufacturing has now been addressed.”